UBS’s XTL Biopharmaceuticals XTLB Stock Holding History

UBS’s Portfolio XTLB Stock Details XTLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-63	Closed	-$4K	–	10820
2014 Q2	$4K	Sell	63 -20	-24%	-$1.32K	﹤0.01%	9701
2014 Q1	$6K	Buy	+83	New	+$6K	﹤0.01%	9404
2013 Q4	–	Sell	-20	Closed	-$2K	–	10816
2013 Q3	$2K	Buy	+20	New	+$2.47K	﹤0.01%	9991

Other funds holding XTLB

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

UBS's XTLB Position: Q3 2014 in Review

UBS sold out of XTL Biopharmaceuticals (XTLB) in Q3 2014, closing a stake of 63 shares — an estimated $4K sold.

UBS first reported a position in XTLB in Q3 2013 and held it in 3 quarters. The position peaked at $6K in Q1 2014. 3 funds tracked by Wall St. Rank hold XTLB as of Q3 2014.

UBS reported no remaining XTL Biopharmaceuticals position as of Q3 2014 after selling out during the quarter.
UBS sold 63 XTL Biopharmaceuticals shares in Q3 2014, an estimated $4K.
UBS first reported a position in XTL Biopharmaceuticals in Q3 2013 and held it in 3 quarters.
UBS's XTL Biopharmaceuticals position peaked at $6K in Q1 2014.
3 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.